AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20930643
Drug: PEG‐IFNα‐2b plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα‐2b plus ribavirin therapy continued post-seizure
Trial: 16704650
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) 5 mg daily
Trial: 9728526
Drug: Valaciclovir 250
RxNorm normalized name: valacyclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 250 mg once daily
Trial: 9728526
Drug: Valaciclovir 1
RxNorm normalized name: valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir 1 g once daily
Trial: 18192785
Drug: Valaciclovir 250
RxNorm normalized name: valacyclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 250 mg twice daily
Trial: 15571711
Drug: Comprehensive, intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive, intensive treatment from 3 to 12 months post-stroke
Trial: 28096757
Drug: PWS (pre-workout
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWS (pre-workout dietary supplement)
Trial: 28096758
Drug: PWS +
RxNorm normalized name: Pulsed Wave Stimulation Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWS + S (pre-workout dietary supplement with p-synephrine)
Trial: 20441061
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg TDS) until the end of 8 weeks gestation (Group B)
Trial: 20441061
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg TDS) stopped immediately after diagnosis of pregnancy (Group A)
Trial: 17022766
Drug: Oral nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nystatin prophylaxis administered three times a day to all neonates (Group B)
Trial: 17022766
Drug: Oral nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nystatin prophylaxis for yeast carriers (Group A1)
Trial: 10947033
Drug: Slow-release caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release caffeine 150 mg
Trial: 29251282
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor antagonist amisulpride
Trial: 21904194
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL sterile water intrathecally
Trial: 21904194
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (200 μg) nalbuphine intrathecally
Trial: 21904194
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (400 μg) nalbuphine intrathecally
Trial: 18982918
Drug: Alendronate (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (once-weekly regimen)
Trial: 8901155
Drug: Test patch
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test patch (Dermestril)
Trial: 1746424
Drug: Pravastatin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, 40 mg/day
Trial: 7048879
Drug: Pindolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (mean dose 28 +/- 5 mg twice a day)
Trial: 7048879
Drug: Methyldopa (673
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (673 +/- 158 mg three times a day)
Trial: 30653147
Drug: Pre-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-administration of remifentanil before propofol infusion (Group R)
Trial: 30653147
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of remifentanil with propofol (Group N)
Trial: 30672195
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture therapy
Trial: 30152573
Drug: Intranasal OXT
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal OXT (24 IU)
Trial: 22669143
Drug: Catuama (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catuama (herbal compound), 2 capsules each day for 8 weeks
Trial: 10642289
Drug: Placebo CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo CPAP (administered at ineffective pressure)
Trial: 3941567
Drug: Saphenous vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saphenous vein grafts with aspirin and dipyridamole
Trial: 29488276
Drug: Exenatide, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide, 5 μg BID for 30 days
Trial: 29488276
Drug: Liraglutide, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide, 3 mg daily for 5 weeks
Trial: 25141246
Drug: Ibuprofen/famotidine fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/famotidine fixed-dose tablet
Trial: 12785122
Drug: Equally single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equally single dosed drugs (ASA and PSE)
Trial: 12785122
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of 500 mg acetylsalicylic acid (ASA) and 30 mg pseudoephedrine (PSE)
Trial: 8862260
Drug: rhuIFN-gamma with
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuIFN-gamma with thalidomide and conventional multidrug chemotherapy
Trial: 8862260
Drug: rhuIFN-gamma without
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuIFN-gamma without concomitant chemotherapy
Trial: 27106721
Drug: DHA+EPA treatment
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA+EPA treatment (4 g/day for 15-18 months)
Trial: 25518878
Drug: Proactive motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive motivational telephone outreach with eight weeks of nicotine replacement therapy and eight sessions of specialized telephone counseling over two months, followed by monthly maintenance counseling for four months.
Trial: 20153158
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost (4 microg, inhaled 6-9 times daily, with a night pause; dose reduced to 2 microg if side effects occurred)
Trial: 31056710
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch alone
Trial: 27052635
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) for 24 weeks (open-label phase)
Trial: 25116690
Drug: Psychotherapy (Narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (Narrative Exposure Therapy)
Trial: 20016870
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin plus amoxicillin‐clavulanate (Group A)
Trial: 18585831
Drug: Pneumococcal vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal vaccine (PV) + Influenza vaccine (IV)
Trial: 18585831
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (IV)
Trial: 15606590
Drug: Vamin 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamin 18 infusion (500 mls) administered immediately after induction of anaesthesia
Trial: 15606590
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Vamin 18 administered)
Trial: 10434232
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate sterile solution (IV infusion)
Trial: 7811160
Drug: Neuroleptic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic medication dose reduction
Trial: 2349364
Drug: Oxazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (10 mg) three times daily for 4 days
Trial: 2349364
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tianeptine and oxazepam
Trial: 25870324
Drug: Typbar-TCV (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typbar-TCV (single dose)
Trial: 25870324
Drug: Typbar (Vi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typbar (Vi polysaccharide, single dose)
Trial: 25870324
Drug: Typbar-TCV (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typbar-TCV (single dose) in OLT
Trial: 24059784
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment for Substance abuse and Partner violence (I-StoP)
Trial: 24059784
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment addressing substance use disorders (CBT-SUD+)
Trial: 7637045
Drug: 2-drug solution
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2-drug solution (papaverine + phentolamine)
Trial: 23223597
Drug: Single-dose tribendimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose tribendimidine
Trial: 11009268
Drug: Pravastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin plus anti-hypertensive drugs
Trial: 11009268
Drug: Hypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertensive agents and diet control alone
Trial: 11009268
Drug: Antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agents (normolipidemia)
Trial: 6175138
Drug: Pimozide treatment
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimozide treatment
Trial: 24571703
Drug: Stannous-containing sodium
RxNorm normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stannous-containing sodium fluoride dentifrice (Oral-B(®) Pro-Expert Sensitive)
Trial: 20221984
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (TA) injection (group B)
Trial: 15637533
Drug: CCI-779 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCI-779 (25, 75, or 250 mg once weekly)
Trial: 11802924
Drug: Valaciclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 1000 mg once daily
Trial: 11802924
Drug: Valaciclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 1000 mg twice daily
Trial: 10233315
Drug: House dust
RxNorm normalized name: House dust
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite (HDM) levels > 2 microgram/g of dust
Trial: 10233315
Drug: House dust
RxNorm normalized name: House dust
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite (HDM) levels between 0.1 and 2 microgram/g of dust
Trial: 10233315
Drug: House dust
RxNorm normalized name: House dust
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite (HDM) levels < 0.1 microgram/g of dust
Trial: 2551242
Drug: CDDP solution
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP solution as usually used
Trial: 30794314
Drug: Peanut patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut patch containing 250 μg of peanut protein (n=238)
Trial: 19922256
Drug: Mud therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud therapy (topical gel prepared using Lake Urmia mud)
Trial: 23141953
Drug: Cervical artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical artificial insemination (CAI): 3×10(9) spermatozoa/80 ml
Trial: 23141953
Drug: Post-cervical artificial
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-cervical artificial insemination (post-CAI 1): 1.5×10(9) spermatozoa/40 ml
Trial: 23141953
Drug: Post-cervical artificial
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-cervical artificial insemination (post-CAI 2): 1×10(9) spermatozoa/26 ml
Trial: 9819168
Drug: Placebo (PL:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL: maltodextrin capsule)
Trial: 8583101
Drug: 5-ASA (Claversal),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA (Claversal), 0.5 g b.i.d.
Trial: 2642669
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate 750 mg daily
Trial: 20297858
Drug: OROS® hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS® hydromorphone administered once daily for up to 52 weeks
Trial: 11923558
Drug: Caffeine capsule
RxNorm normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine capsule (200 mg)
Trial: 9459251
Drug: Intraarticular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine (5 mg) with intraarticular bupivacaine (30 mL of 0.25%)
Trial: 9459251
Drug: Intraarticular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine (5 mg) with normal saline (30 mL)
Trial: 9459251
Drug: Intraarticular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular bupivacaine (30 mL of 0.25%)
Trial: 9459251
Drug: Intraarticular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular bupivacaine (30 mL of 0.25%) with intravenous morphine (5 mg)
Trial: 14618054
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of curved and straight shaft catheters
Trial: 10753829
Drug: PEG‐rHuMGDF (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rHuMGDF (3 microg/kg, single bolus subcutaneous injection)
Trial: 27341795
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of chemotherapy
Trial: 27341795
Drug: Chemotherapy scheme
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy scheme
Trial: 22907974
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus Docetaxel (Gemcitabine 900 mg/m² i.v. for 90 minutes on days 1 and 8, plus Docetaxel 100 mg/m² i.v. for 1 hour on day 8 of a 21-day cycle with lenograstim)
Trial: 20081039
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg three times per day
Trial: 18076806
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with concurrent radiotherapy
Trial: 20113303
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behaviour Therapy (CBT)
Trial: 10474848
Drug: No-therapy control
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-therapy control group
Trial: 8942598
Drug: Univent tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Univent tube with bronchial blocker
Trial: 9476039
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pyridostigmine
Trial: 26084276
Drug: Miglustat 100
RxNorm normalized name: miglustat 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat 100 mg t.i.d. + S. boulardii 500 mg b.i.d.
Trial: 26084276
Drug: Miglustat 100
RxNorm normalized name: miglustat 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat 100 mg t.i.d. + placebo
Trial: 23351522
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and Olanzapine
Trial: 30361250
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and Placebo
Trial: 18259972
Drug: Arformoterol 15
RxNorm normalized name: arformoterol 15 mcg/2 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arformoterol 15 micro g BID
Trial: 18259972
Drug: Arformoterol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arformoterol 25 micro g BID
Trial: 18259972
Drug: Arformoterol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arformoterol 50 micro g QD
Trial: 18259972
Drug: Salmeterol 42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 42 micro g BID
Trial: 9165581
Drug: 560 mg
RxNorm normalized name: spinosad 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg estramustine phosphate (EMP) per day
Trial: 9165581
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg diethylstilbestrol (DES) per day
Trial: 9835726
Drug: Nonsteroidal antiinflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal antiinflammatory drugs (NSAIDs)
Trial: 2903827
Drug: Oral dosing
RxNorm normalized name: oral dosing devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of xamoterol
Trial: 2903827
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of pharmacokinetics in cardiac failure patients vs young healthy male volunteers
Trial: 27237709
Drug: Ferric maltol
RxNorm normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferric maltol 30 mg b.d. for 52 weeks
Trial: 23276888
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) with oral calcium and vitamin D supplementation
Trial: 17655781
Drug: Physostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (30 µg kg-1)
Trial: 15178717
Drug: 25,000 IU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25,000 IU/mL r‐UK
Trial: 15178717
Drug: 15,000 IU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15,000 IU/mL r‐UK
Trial: 15178717
Drug: 5,000 IU/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU/mL r‐UK
Trial: 8450459
Drug: Triazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.5 mg/70 kg)
Trial: 8450459
Drug: Triazolam (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.75 mg/70 kg)
Trial: 8450459
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 mg/70 kg)
Trial: 23303874
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg daily)
Trial: 8243878
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (65 micrograms/kg)
Trial: 2938849
Drug: Selective inhibitor
RxNorm normalized name: EGFR MUTANT-SELECTIVE INHIBITOR BLU-945
DrugBank: Tigozertinib (DB19239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective inhibitor of thromboxane synthase, imidazo (1,5‐2) pyridine‐5‐hexanoic acid, administered under randomized, double‐blind, controlled conditions.
Trial: 2938849
Drug: Aspirin (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (as a control for platelet cyclooxygenase inhibition)
Trial: 2938849
Drug: Long-term dosing
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term dosing with the synthetic inhibitor of thromboxane synthase
Trial: 2938849
Drug: Thromboxane synthase
RxNorm normalized name: Thromboxane synthase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboxane synthase inhibitor
Trial: 25947202
Drug: Peer mentoring
RxNorm normalized name: IRRIGATOR,GREER MENTOR #6004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer mentoring intervention to reduce teenage pregnancy; details on dosage and duration not available.
Trial: 23911273
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose-adjustment (CDA) according to PR monitoring
Trial: 21996146
Drug: Prasugrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel therapy
Trial: 22235508
Drug: Biguanide (metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biguanide (metformin 500 mg three times daily)
Trial: 22235508
Drug: Statin (simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (simvastatin 20 mg daily)
Trial: 22235508
Drug: Biguanide (metformin)
RxNorm normalized name: biguanide
DrugBank: Biguanide (DB13100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biguanide (metformin)
Trial: 16217850
Drug: Frequent assessment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent assessment (16 postbaseline visits, twice-weekly for 8 weeks)
Trial: 15271855
Drug: 50% decreased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% decreased vegetable intake (75 g/day) for 2 weeks
Trial: 15271855
Drug: Doubled vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubled vegetable intake (300 g/day) for 2 weeks